.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J06A_ImmuneSera.J06AA04_BotulinumAntitoxin.BotulinumAntitoxin .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J06A_ImmuneSera.J06AA04_BotulinumAntitoxin.BotulinumAntitoxin| name: | BotulinumAntitoxin |
| ATC code: | J06AA04 | route: | intravenous |
| n-compartments | 2 |
Botulinum antitoxin is an equine-derived immunoglobulin preparation used for the treatment of botulism, a rare but serious illness caused by botulinum toxin. It acts by binding to circulating toxin molecules, neutralizing their effect and limiting disease progression. The drug is used primarily in post-exposure therapy for botulism and is approved for this purpose by relevant health authorities.
No published pharmacokinetic data is available for botulinum antitoxin preparations (heptavalent, equine-derived) in humans. Pharmacokinetic values below are not based on primary literature but reflect expected values for large immunoglobulin proteins administered intravenously in adults.